ArticleClinical and experimental medicine2026
Impact of albumin infusion on 30-day mortality in ICU patients with acute-on-chronic liver failure: a retrospective cohort using MIMIC-IV database.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human serum albumin (HSA) possesses oncotic, antioxidant, and immunomodulatory properties. Although recent studies suggest that albumin may promote resolution of acute-on-chronic liver failure (ACLF) and reduce the incidence of infection, its impact on overall prognosis with daily administration remains unestablished. Patients meeting the Asian Pacific Association for the Study of the Liver (APASL) criteria for ACLF were extracted from the Medical Information Mart for Intensive Care (MIMIC-IV 2.2) database. The primary outcome was 30-day mortality. To balance baseline characteristics between the albumin and non-albumin groups, we applied stabilized inverse probability of treatment weighting (SIPTW). The association between daily albumin infusion and 30-day mortality was subsequently assessed using Cox regression analyses. A total of 505 patients were enrolled in the study, of whom 325 received albumin therapy within the first 24 h of ICU admission. After applying SIPTW, the cohort comprised 169 patients in the non-albumin group and 319 in the albumin group. Overall, albumin administration was not significantly associated with 30-day mortality in patients with ACLF. However, subgroup analyses revealed that albumin infusion conferred the most substantial survival benefit in specific patient populations. These included individuals with spontaneous bacterial peritonitis, a Model for End-Stage Liver Disease score of ≥ 30.1, a mean arterial pressure below 73 mmHg, a daily albumin dosage of ≤ 1.0 g/kg, or those receiving a combination of 5% and 25% albumin concentrations. Conversely, a dosage exceeding 1.0 g/kg/day was associated with inferior 30-day survival. Albumin administration is associated with reduced mortality in specific subpopulations of patients with ACLF. Key clinical parameters-including serum albumin concentration, SBP, MELD score, and MAP-were identified as significant modifiers of treatment efficacy and should be incorporated into clinical decision-making when initiating albumin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.